NOVN.CH

116.58

+1.57%↑

SOON.CH

209

+1.55%↑

NOVN.CH

116.58

+1.57%↑

SOON.CH

209

+1.55%↑

NOVN.CH

116.58

+1.57%↑

SOON.CH

209

+1.55%↑

NOVN.CH

116.58

+1.57%↑

SOON.CH

209

+1.55%↑

NOVN.CH

116.58

+1.57%↑

SOON.CH

209

+1.55%↑

Inicio・Lista de Acciones・Lonza Group AG
Search

Lonza Group AG

Abierto

SectorSanidad

494.3 1.29

Compra Fuerte

Precios actualizados 5 jun 2026, 09:16 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

485.3

Máximo

494.3

Métricas clave

By Trading Economics

Ingresos

57M

483M

Ventas

-621M

3B

P/B

Media del Sector

38.14

49.888

Rentabilidad por dividendo

1

Margen de beneficios

16.345

Empleados

20,000

EBITDA

-181M

822M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+35.82% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.00%

2.38%

Próximas Ganancias

22 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-4.1B

35B

Apertura anterior

493.01

Cierre anterior

494.3

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

155 / 344 Clasificación en Healthcare

Lonza Group AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 mar 2026, 17:44 UTC

Adquisiciones, fusiones, absorciones

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

DJ

Leer

28 ene 2026, 06:15 UTC

Ganancias

Lonza Sales Grow on New Contract Momentum

DJ

Leer

23 jul 2025, 08:30 UTC

Ganancias
Principales Movimientos del Mercado

Lonza Shares Rise After Outlook Lift for Core Business

DJ

Leer

15 may 2026, 10:45 UTC

Charlas de Mercado

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

DJ

Leer

8 may 2026, 13:44 UTC

Charlas de Mercado
Ganancias

Lonza Update Should Reassure on Outlook -- Market Talk

DJ

Leer

9 mar 2026, 10:34 UTC

Charlas de Mercado

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

DJ

Leer

6 mar 2026, 17:12 UTC

Adquisiciones, fusiones, absorciones

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

DJ

Leer

6 mar 2026, 17:10 UTC

Adquisiciones, fusiones, absorciones

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

DJ

Leer

6 mar 2026, 17:09 UTC

Adquisiciones, fusiones, absorciones

Lonza to Retain 40% Stake in CHI

DJ

Leer

6 mar 2026, 17:08 UTC

Adquisiciones, fusiones, absorciones

Lonza Will Receive Upfront Proceeds of CHF1.7B

DJ

Leer

6 mar 2026, 17:07 UTC

Adquisiciones, fusiones, absorciones

Lonza: Transaction Expected to Close in 2H

DJ

Leer

6 mar 2026, 17:07 UTC

Adquisiciones, fusiones, absorciones

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

DJ

Leer

6 mar 2026, 17:06 UTC

Adquisiciones, fusiones, absorciones

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

DJ

Leer

28 ene 2026, 12:04 UTC

Charlas de Mercado
Ganancias

Lonza Results Show a Company in Good Shape -- Market Talk

DJ

Leer

28 ene 2026, 05:35 UTC

Ganancias

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

DJ

Leer

28 ene 2026, 05:34 UTC

Ganancias

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

DJ

Leer

28 ene 2026, 05:33 UTC

Ganancias

Lonza Issues 2026 View

DJ

Leer

28 ene 2026, 05:32 UTC

Ganancias

Lonza 2025 Core Ebitda Margin 31.6%

DJ

Leer

28 ene 2026, 05:32 UTC

Ganancias

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

DJ

Leer

28 ene 2026, 05:32 UTC

Ganancias

Lonza 2025 Core Ebitda CHF2.06B

DJ

Leer

28 ene 2026, 05:30 UTC

Ganancias

Analysts Saw Lonza 2025 Sales at CHF7.54B

DJ

Leer

28 ene 2026, 05:30 UTC

Ganancias

Lonza 2025 Sales CHF6.53B

DJ

Leer

27 oct 2025, 08:24 UTC

Charlas de Mercado

Lonza on Track to Meet Long-Term Goals -- Market Talk

DJ

Leer

23 oct 2025, 10:53 UTC

Charlas de Mercado
Ganancias

Lonza Set to Recover as Contracts Flow in -- Market Talk

DJ

Leer

23 jul 2025, 08:00 UTC

Charlas de Mercado
Ganancias

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

DJ

Leer

23 jul 2025, 04:44 UTC

Ganancias

Lonza 1H Sales Grew 19% at Constant Currency

DJ

Leer

23 jul 2025, 04:43 UTC

Ganancias

Lonza 1H Core Ebitda Margin 29.6%

DJ

Leer

23 jul 2025, 04:43 UTC

Ganancias

Lonza: Margins Will Be Only Minimally Affected

DJ

Leer

23 jul 2025, 04:42 UTC

Ganancias

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

DJ

Leer

23 jul 2025, 04:42 UTC

Ganancias

Lonza: This Is Mainly From Weakening of U.S. Dollar

DJ

Leer

Comparación entre iguales

Cambio de precio

Lonza Group AG previsión

Precio Objetivo

By TipRanks

35.82% repunte

Estimación a 12 Meses

Media 664 CHF  35.82%

Máximo 762 CHF

Mínimo 590 CHF

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lonza Group AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Lonza Group AG Dist en los últimos 3 meses.

Sentimiento

By Acuity

155 / 344 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Otras acciones del sector

NOVN.CH

Novartis AG

116.58

↑ +1.57%

SOON.CH

Sonova Holding AG

209

↑ +1.55%